

WEDNESDAY 3RD OCTOBER

SESSION 1

13:30 - 13:45	Welcome Sigbjørn Smeland & Stein Kaasa
13:45 - 14:15	Targeting the tumor microenvironment with anti-regulatory T cells Mads Hald Andersen, Copenhagen University Hospital Herlev, Denmark
14:15 - 14:45	The myeloid intervention in metastatic process Vincenzo Bronte, University of Verona, Italy
14:45 - 15:15	2X Proffered papers
15:15 - 15:30	Coffee Break
15:30 - 16:00	Immunoregulatory circuits in melanoma and their neutralization Viktor Umansky, Faculty for Biosciences, University of Heidelberg, Germany
16:00 - 16:30	2X Proffered papers
16:30 - 16:45	Coffee Break

SESSION 2

16:45 - 17:15	What does tumor innervation mean? Michael Shurin, University of Pittsburgh, USA
17:15 - 17:45	TBA Sue Ostrand-Rosenberg, University of Maryland, USA
17:45 - 18:15	2X Proffered papers
19:00 -	Get together

THURSDAY 4TH OCTOBER

SESSION 3

PRE-CLINICAL

09:00 - 09:30	CD4+ T cells in the microenvironment and tumour rejection Bjarne Bogen, Oslo University Hospital, Norway
09:30 - 10:00	New approaches against AML, EBV and CMV and preclinical testing in humanized mice Renata Striepcke, Hannover Medical School, Germany
10:00 - 10:30	2X Proffered papers
10:30 - 11:30	Poster session and coffee
11:30 - 12:00	Immunotherapy for patients with HPV-induced cancer Marij Welters, Leiden University Medical Center, Netherlands
12:00 - 12:30	TBC - Glioblastoma vaccine + anti-PD-1 Valérie Dutoit, University of Geneva, Switzerland
12:30 - 13:00	Pre-clinical models for melanoma and osteosarcoma immunotherapy: Dawn of the dogs' revolution Federica Cavallo, University of Turin, Italy
13:00 - 14:00	Lunch

VACCINES

14:00 - 14:30	Immunomonitoring as a tool to identify biomarkers predicting the outcome of immunotherapy treated patients Cécile Gouttefangeas, University of Tübingen, Germany
14:30 - 14:45	1X Proffered paper
14:45 - 15:15	The tumor microenvironment in HPV-induced cancer: implications for immunotherapy Saskia Santegoets, Leiden University Medical Center, Netherlands
15:15 - 16:15	Poster session and coffee
16:15 - 16:45	HLA class I loss and cancer immune escape: Rediscovering an old story Federico Garrido, University of Granada, Spain
16:45 - 17:15	Mechanisms and clinical relevance of immune escape of tumors and its role in immunotherapies Barbra Seliger, Martin-Luther-University Halle-Wittenberg, Germany
17:15 - 17:45	Towards a synthetic immune system to fight cancer Carl Figdor, Radboud University Nijmegen Medical Centre, Netherlands
19:00 -	Conference reception - POSTER PRIZE

FRIDAY 5TH OCTOBER

SESSION 5

09:00 - 09:30	Synergy of therapeutic vaccination, chemotherapy and checkpoint blocking Cornelis Melief, Leiden University Medical Center, Netherlands
09:30 - 10:00	Combining TIL therapy and DC vaccination of advanced malignant melanoma Rolf Kiessling, Karolinska Institute, Sweden
10:00 - 10:30	TBC - Clinical trial ACT melanoma Michael Nishimura, Loyola University Chicago Stritch School of Medicine, USA
10:30 - 10:45	Coffee Break
10:45 - 11:15	Immunopeptidomics: Accelerating the development of personalized cancer immunotherapy Michal Bassani-Sternberg, Ludwig Institute for Cancer Research Lausanne, Switzerland
11:15 - 11:45	TBC - RNA vaccine platform Christian Grunwitz TRON, University Medical Center Mainz, Germany
11:45 - 12:15	TBA Costas Baxevanis, St. Savvas Hospital Athens, Greece
12:15 - 12:45	2X Proffered papers
12:45 - 14:00	Lunch
14:00 - 14:30	Optimizing T cell responses to multipeptide cancer vaccines Craig Slingluff, University of Virginia School of Medicine, USA
14:30 - 15:00	TBA Olivier Adotévi, University Hospital of Besancon, France
15:00 - 15:30	CMV infection, cancer and survival in the elderly Graham Pawelec, University of Tübingen, Germany
15:30 - 15:45	Coffee Break
15:45 - 16:15	TBC - DC vaccines Gunnar Kvalheim, Oslo University Hospital, Norway
16:15 - 16:45	TBA Gustav Gaudernack, University of Oslo, Norway